<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03564964</url>
  </required_header>
  <id_info>
    <org_study_id>EAP1502HT6</org_study_id>
    <nct_id>NCT03564964</nct_id>
  </id_info>
  <brief_title>Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease</brief_title>
  <acronym>SUVN-502</acronym>
  <official_title>An Intermediate-Size, Expanded Access to SUVN-502 for the Treatment of Subjects With Alzheimer's Disease Who Have Completed the CTP2S1502HT6 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suven Life Sciences Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suven Life Sciences Limited</source>
  <brief_summary>
    <textblock>
      This is an expanded access program (EAP) for eligible participants. This program is designed
      to provide access to SUVN-502 for the treatment of Alzheimer's Disease. Investigator as well
      as the subject/caregiver must decide whether the potential benefit outweighs the risk of
      receiving an investigational therapy based on the patient's medical history and program
      eligibility criteria.

      Subjects will not be evaluated for efficacy and safety during the expanded access.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Alzheimer Disease</condition>
  <condition>Dementia</condition>
  <condition>Cognition Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUVN-502</intervention_name>
    <description>Tablet</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have completed the 30 week treatment period of study CTP2S1502HT6 as
             planned and wish to continue treatment with SUVN-502.

          -  Subject (or subject's legally acceptable representative) and caregiver must sign the
             Informed Consent Form (ICF) to participate in the study.

        Exclusion Criteria:

          -  Has participated or is participating in any other clinical (investigational) study
             after completion of CTP2S1502HT6 study.

          -  Is treated or likely to require treatment during the study with any medication
             prohibited by this expanded access program.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Ramakrishna Nirogi</last_name>
    <phone>+91 9392483002</phone>
    <email>suvn502study@suven.com</email>
  </overall_contact>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 28, 2018</study_first_submitted>
  <study_first_submitted_qc>June 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>September 21, 2019</last_update_submitted>
  <last_update_submitted_qc>September 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SUVN-502</keyword>
  <keyword>Expanded Access</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

